SEC Filing Summary: Healthcare Acquisition Corp. (HAQ)
Business Context and Reporting Period
This Form 8-K was filed by Healthcare Acquisition Corp. (HAQ) on May 2, 2007. The report discloses the adoption of Rule 10b5-1 stock purchase plans by three founders, officers, and directors of the company. The filing does not contain financial statements or operational results for a specific reporting period.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on insider trading plans rather than financial performance.
Material Changes and Insider Activity
On May 2, 2007, the following insiders adopted plans to purchase shares on the open market:
- John Pappajohn: Up to 100,000 shares (Daily limit: 10,000 shares).
- Derace Schaffer: Up to 100,000 shares (Daily limit: 10,000 shares).
- Matt Kinley: Up to 50,000 shares (Daily limit: 5,000 shares).
Aggregate Limits: The total number of shares to be purchased will not exceed 250,000. A daily purchase limit of 25,000 shares applies across all individuals. The maximum purchase price is set at $7.60 per share. The plans expire on August 3, 2007.
Guidance, Outlook, and Risks
The filing contains no management guidance, outlook, or discussion of risks and contingencies. The document serves solely to disclose the intent of insiders to purchase stock under a pre-arranged plan to comply with SEC Rule 10b5-1.
Investor Verification Checklist
- Verify the current market price of HAQ stock relative to the $7.60 purchase cap.
- Monitor subsequent filings to confirm if the 250,000 share purchase limit was reached before the August 3, 2007 expiration.
- Confirm the current status of the company, as the metadata mentions "Altimmune, Inc." while the filing is for "Healthcare Acquisition Corp."